How c-Maf promotes immunoregulation of PD-1-expressed TAMs or CD8+ T cells in NSCLC patients is still unknown, while it has been already been demonstrated in multiple sclerosis and relapsed/refractory classic Hodgkin lymphoma [39, 40]. This evidence concerns the gene MAF and non-small cell lung carcinoma.